PharmSight Strengthens Global Footprint with New Office in Zug (Switzerland); Launches Conversity’s AI Training Platform
PharmSight Research & Analytics today announces the opening of its European hub in Zug, Switzerland. Operating as PharmSight GmbH, this strategic expansion reinforces the company’s commitment to deliver data-driven insights for negotiation training, sales force optimization, and market access solutions in the heart of Europe’s pharmaceutical ecosystem.
Leading PharmSight GmbH is Mr Gianclaudio Floria, recently appointed CEO with over 20 years of experience in commercial operations and strategic roles at industry giants like Amgen, BMS, Fresenius Kabi, Gilead, and Alexion. A published author and recognized thought leader, Mr. Floria brings extensive international expertise in Finance, M&A, Strategic Planning, and Market Access, reinforcing PharmSight’s vision for Europe.
A cornerstone of the Zug launch is the debut of Conversity, an AI-driven training platform that leverages ultra-realistic avatars, scenario-based simulations, and real-time analytics to elevate negotiation and sales performance. Conversity helps professionals navigate complex agreements, optimize market access, and refine sales engagement. With this addition to its European portfolio, PharmSight further cements its role as a trusted partner in the region’s pharmaceutical landscape.
“Our Zug office marks a significant step in our global journey,” said Siddharth Pathela, Co-founder of PharmSight. “We’re excited to unveil Conversity, the latest addition to our proprietary AI toolkit – Intellisight, Pharmlens, Pharmalert, and Cintel. Conversity is set to transform negotiation and sales training, delivering strong value to the biopharma sector.”
This milestone follows PharmSight’s recent launch in the U.S. market. With offices in Boston and now Zug, PharmSight is planning expansion into the Middle East and establishing an innovation center focused on AI/ML.
About PharmSight
PharmSight is a global consulting firm serving the biopharmaceutical industry through advanced data management and analytics, forecasting, CI, HEOR, reporting automation, patient analytics, and AI-driven solutions. Headquartered in Gurugram, India, with offices in Boston and Zug, PharmSight’s 50+ consultants collaborate with clients worldwide to transform data into actionable insights.
About Conversity
Conversity is an AI-powered negotiation training platform designed specifically for the pharmaceutical sector. With its immersive simulations, customized scenarios, and in-depth analytics, Conversity equips professionals to master negotiation skills, enhance market access, and achieve superior sales performance.
For more information, please visit www.pharmsight.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250616604727/en/
Contacts
Gianclaudio Floria
g.floria@pharmsight.com
Rachit Syag
Rachit@pharmsight.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing17.6.2025 14:00:00 EEST | Press release
In response to Harbour BioMed’s recent press release regarding a procedural development in their ongoing legal claim, Biocytogen issues the following statement: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617098086/en/ Figure 1. Biocytogen’s RenNano® Platform Genetic Engineering Strategy (Source: https://biocytogen.com/antibody-drug-development/rennano） Biocytogen stands by its core values of independent innovation, respect for intellectual property, and a commitment to fair competition. The RenNano® platform is the result of independent, original R&D, based on Biocytogen’s proprietary genome editing technologies. Its technical principles, design strategy, and IP scope are fundamentally different from the patents in dispute. 120 vs. 9 – A Significant Technical Divide of RenNano® Platform; Biocytogen Will Resolutely Take Legal Actions to Protect Its Rights The RenNano® platform employs a large-fragment knock-in strategy
EDB Postgres ® AI Accelerates New Era of Sovereign Data and AI for Enterprises, Industries, and Nations17.6.2025 14:00:00 EEST | Press release
EnterpriseDB (EDB), the leading Postgres data and AI company, today announced new innovations to the EDB Postgres AI (EDB PG AI) platform designed to help enterprises deploy and scale AI securely and compliantly across their Postgres environments, whether in clouds or on-premises. The platform streamlines operations at scale, integrates easily with existing data ecosystems, and centralizes hybrid management and observability in a single AI-ready control plane for the emerging era of agentic AI. See the demonstrations and configure your sovereign AI and platform at www.enterprisedb.com. EDB PG AI is a unified platform with an easy-to-use interface for managing transactional, analytical, and AI workloads. As the industry’s first Postgres-based sovereign data and AI platform, it unifies relational and non-relational data in a single system, featuring automatic pipelines and built-in development tools that seamlessly automate and operationalize data for AI. “In this AI-first, sovereign-fir
G42 and Liquid AI Partner to Deliver Private, Local and Efficient AI Solutions to Enterprises at Scale17.6.2025 13:00:00 EEST | Press release
G42, the Abu Dhabi-based global technology group, and Liquid AI, a leading efficient foundation models company headquartered in Cambridge, Massachusetts, today announced that they have entered into a multifaceted commercial partnership to facilitate the creation, training and commercialization of generative AI solutions powered by Liquid Foundation Models. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617744482/en/ The goal of the partnership is to jointly develop and deploy private generative AI solutions internationally, from the Middle East and North Africa to the Global South, and across many sectors, such as investment and banking, consumer electronics, telecommunications, biotech, and energy. G42 companies such as Core42 and Inception are involved in various aspects of the partnership, from AI infrastructure for AI development to co-designing multimodal foundation models and deployment. “This partnership reflects o
Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)17.6.2025 11:28:00 EEST | Press release
Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development of progressive supranuclear palsy (PSP), has received Fast Track designation from the US Food & Drug Administration (FDA). FNP-223, a new molecular entity in active development for PSP, is in an ongoing Phase 2 study to evaluate its safety, efficacy, and pharmacokinetics in adult patients with possible or probable PSP-Richardson syndrome (PSP-RS), the most common clinical variant of this neurodegenerative disease1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617437460/en/ Ferrer's pharmaceutical production plant in Sant Cugat del Vallés, Barcelona, Spain. “We are thrilled to receive Fast Track designation from the FDA for FNP-223 in the treatment of PSP. Consistent with our purpose of using business to fight for social justice, we are committed to
Aqara Smart Lock U200 Lite Brings Smart Access Control to More European Households17.6.2025 10:00:00 EEST | Press release
Aqara, global leader and pioneer in IoT, unveils the new Smart Lock U200 Lite, offering effortless access control, enhanced security, and a modern keyless lifestyle to more European households, particularly those seeking budget-friendly solutions. Designed for DIY installation, the U200 Lite features a retrofit design compatible with most Euro mortise locks. It also supports Matter over Thread to ensure compatibility with a wide range of connected devices and seamless integration into users’ existing smart home setup. Built upon the Thread protocol, which is purposely developed for IoT devices, the Smart Lock U200 Lite is Matter-certified and integrates with major platforms – including Alexa, Apple Home, Google Home, Home Assistant, and SmartThings – without the need for a proprietary hub1. As an integral part of a connected home, the U200 Lite can be integrated with a variety of smart devices, from video doorbells, surveillance cameras to smart sensors, enabling users to create a cust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom